A5013446377- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Functional Brain Connectivity Studies
- Memory and Neural Mechanisms
- Health Systems, Economic Evaluations, Quality of Life
- Health disparities and outcomes
- Chronic Disease Management Strategies
- Stroke Rehabilitation and Recovery
- Schizophrenia research and treatment
- Clinical Reasoning and Diagnostic Skills
- Ophthalmology and Visual Impairment Studies
- Frailty in Older Adults
- Neurological Disease Mechanisms and Treatments
- Neuroinflammation and Neurodegeneration Mechanisms
- Healthcare cost, quality, practices
- Diet and metabolism studies
- Aging and Gerontology Research
- Health, Environment, Cognitive Aging
University of Bonn
2013-2019
German Center for Neurodegenerative Diseases
2015-2019
Leipzig University
2016
Central Institute of Mental Health
2015-2016
Universität Hamburg
2015-2016
Heidelberg University
2015-2016
University Medical Center Hamburg-Eppendorf
2016
Medizinische Hochschule Hannover
2016
Klinikum rechts der Isar
2016
Technical University of Munich
2016
Our objectives were (1) to test the association between report of subjective cognitive decline (SCD) and prospective objective performance in high age individuals (2) study course longitudinal before after first SCD.Cognitively normal elderly participants German Study on Ageing, Cognition, Dementia (N = 2330) with SCD (subjective memory without associated concerns) at baseline assessed over 8 years regard immediate delayed verbal recall, fluency, working memory, global cognition. Baseline...
Abstract Background Individuals with subjective memory impairment (SMI) report worsening of without in cognitive tests. Despite normal performance, they may be at higher risk decline compared individuals SMI. Methods We used a discriminative function (a support vector machine) trained on an independent data set 226 healthy control subjects and 191 patients probable Alzheimer's disease (AD) dementia to characterize the baseline gray matter patterns 24 SMI 53 subjects. tested for associations...
There is very limited data on the prevalence of abnormal cerebrospinal fluid (CSF) biomarkers Alzheimer's disease (AD) and their predictive value for clinical progression in memory clinic patients with subjective cognitive decline (SCD).To assess frequency CSF AD SCD comparison to mild impairment (MCI) from same cohort.We analyzed prospective German Competence Network Dementia cohort a baseline diagnosis (n = 82) or MCI 134), distinguished by actuarial neuropsychological criteria ("Jak-Bondi...
<h3>Background</h3> In older patients with chronic diseases, focusing on subjective, patient-relevant outcomes, such as health-related quality of life (HRQoL), is more pertinent than pursuing clinical or laboratory target values. <h3>Aim</h3> To investigate factors influencing the course HRQoL in (aged ≥78 years) primary care and to derive non-pharmacological recommendations for improving their life. <h3>Design setting</h3> A population-based prospective longitudinal observational study...
Background: Feature binding is a sensitive and specific cognitive marker for Alzheimer's disease (AD). Subjective decline (SCD) mild impairment (MCI) are clinical categories associated with an increased risk AD. Objective: To investigate whether the SCD MCI group impaired regard to feature binding. Methods: The test was administered memory clinic patients either (n = 19, mean MMSE: 29.2) or 23, 26.5), of healthy controls (HC, n 29.0). Participants were assessed CERAD Plus neuropsychological...
To test whether, in individuals with mild cognitive impairment (MCI), different measures of subjective decline (SCD) the memory domain predict abnormal CSF biomarkers Alzheimer disease (AD).We analyzed multicenter baseline (cross-sectional) data 245 patients MCI. SCD was measured quantitatively Subjective Memory Decline Scale (SMDS) and qualitatively by assessing particular concerns associated self-experienced worsening memory. Logistic regression models were used to examine associations...
Subjective cognitive decline (SCD) patients are considered as a risk population for preclinical Alzheimer's Disease (AD). Supporting this idea, previous studies in SCD populations report subtle alterations various and neuroimaging biomarkers that typically affected during AD progression. To extend these observations, the present study examined whether show atrophy of cholinergic basal forebrain nuclei (chBFN), analogous with recent findings prodromal clinical patients. We assessed volume...
Objectives To examine how visual impairment affects physical and cognitive function in old age. Design A longitudinal population‐based prospective cohort study. Setting General practitioner offices at six study centers Germany. They were observed every 1.5 years over four waves. Participants Individuals aged 77–101 follow‐up Wave 2 (N = 2,394). Measurements Physical assessed using an adapted scale that had been previously developed, was rated on a Likert (none, mild, severe or profound)....
There is a need for more sensitive neuropsychological tests to detect subtle cognitive deficits emerging in the preclinical stage of Alzheimer's disease (AD). Associative memory function supported by hippocampus and affected early process AD.We developed short computerized face-name associative recognition test (FNART) tested whether it would impairment clinic patients with mild (MCI) subjective decline (SCD).We recruited 61 elderly either SCD (n = 32) or MCI 29) 28 healthy controls (HC)...
Introduction Previous studies have demonstrated that an overall high level of mental work demands decreased dementia risk. In our study, we investigated whether this effect is driven by specific and it exposure dependent. Methods Patients aged 75+ years were recruited from general practitioners participated in up to seven assessment waves (every 1.5 years) the longitudinal AgeCoDe study. Analyses impact on risk carried out via multivariate regression modeling (n = 2315). Results We observed...
Background: The recently proposed latent variable δ is a new tool for dementia case finding. It built in structural equation modeling framework of cognitive and functional data constitutes novel endophenotype Alzheimer’s disease (AD) research clinical trials. Objective: To investigate the association with AD biomarkers to compare prediction established scales conversion patients mild impairment (MCI). Methods: Using from multicenter memory clinic study, we examined external associations...
Subjective cognitive decline (SCD) might represent the first symptomatic representation of Alzheimer's disease (AD), which is associated with increased mortality. Only few studies, however, have analyzed association SCD and mortality, if so, based on prevalent cases. Thus, we investigated incident in memory mortality.Data were derived from German AgeCoDe study, a prospective longitudinal study epidemiology mild impairment (MCI) dementia primary care patients over 75 years covering an...
Clinical judgement is intrinsic to diagnostic strategies in general practice; however, empirical evidence for its validity sparse.To ascertain whether a GP's global clinical of future cognitive status has an added value predicting patient's likelihood experiencing dementia.Multicentre prospective cohort study among patients German practice that took place from January 2003 October 2016.Patients without baseline dementia were assessed with neuropsychological interviews over 12 years; 138 GPs...
Impaired visual feature binding has recently been proposed as a sensitive and specific cognitive marker for early stages of Alzheimer Disease (AD), based on data from AD patients asymptomatic carriers mutations. In order to examine also in at risk AD, where detection is particularly important, we studied with subjective decline (SCD) amnestic MCI (aMCI). Memory clinic SCD (cognitive performance within 1 SD the normative mean standard neuropsychological testing, n=20, age 68 years), aMCI...
Subjective memory impairment (SMI) is considered a risk factor for conversion into dementia. This longitudinal study investigates the predictive effects of SMI with concerns and without on objective cognitive decline. Data from six waves primary care-based, prospective AgeCoDe was used. Subjects included in this analysis were not demented MCI at baseline (N=2319, mean age 79,7 years baseline, 64%female, MMSE 27,95) followed up over 95 months (five intervals approx. 18 months). Latent growth...
Cognitively normal elderly with Subjective Cognitive Decline (SCD) have an increased risk to develop dementia, as suggested by many studies a single cross-sectional measurement of SCD. However, because Alzheimer's disease (AD) is constantly progressing disease, and the reliability SCD may be limited, longitudinal assessment contribute further information regard AD dementia risk. We hypothesized that individuals who repeatedly report should higher AD, compared those unstable pattern reports....
There is a need for sensitive neuropsychological tests to uncover the subtle cognitive deficits emerging during late preclinical stage of Alzheimer's disease. Associative memory, binding together previously unrelated information, supported by hippocampus and might be function that affected early in In this study we applied new computerized face-name associative recognition test (FNART) capture putative changes memory clinic patients with Subjective Cognitive Decline (SCD). Sixty-one from...
Physical and cognitive activity modify the risk of Alzheimer's Dementia (AD) in elderly. Here, we tested magnitude modification by these types at different stages dementia. These are subjective decline (SCD) with associated worries (SCDw) without (SCDnw) as well mild impairment (MCI). Data German study on ageing, cognition dementia primary care patients (AgeCoDe) covering 4,5 years (three follow-up examinations) was analyzed. Only dementia-free subjects baseline were included (n=2526). The...
The recently proposed latent variable δ reflects the dementing process in patients with Alzheimer's disease (AD). It is modeled a structural equation modeling framework (SEM) of cognitive and functional data constitutes novel endophenotype for AD research clinical trials. has been associated default mode network (DMN), dementia severity as rated by CDR prevalent samples from different cultures. However, it unknown whether can compete established measures association biomarkers cerebrospinal...
TREM2 is discussed as a new genetic risk factor for Alzheimer's dementia. This study aims to evaluate the impact of rare variants (A105Rfs*84,D87N,Q33*, R47H, R62C, R62H, T85I) on cognitive decline and time AgeCoDe GP based, prospective longitudinal study. Mean age carriers: 83, female: 82%, mean non-carriers: 80, 65 % females. Subjects included three groups: demented carriers (n=10); age, gender, education, dementia point MMSE baseline performance matched non-carriers (n=270), cognitively...
Subjective Cognitive Decline (SCD) in cognitively unimpaired individuals may represent the first symptomatic manifestation of Alzheimer's disease (AD) before mild cognitive impairment (MCI) occurs. For a useful SCD operationalization robust distinction between performance and MCI is critical. Jak Bondi (2009) have proposed neuropsychological criteria that balance sensitivity reliability diagnosis. We applied these to classify memory clinic patients into “robust MCI” (rMCI) vs. SCD, compared...